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Abstract
Background: Evaluation of resection margins during cancer surgery can be challenging, often resulting in incomplete
tumour removal. Fluorescence-guided surgery (FGS) aims to aid the surgeon to visualize tumours and resection margins
during surgery. FGS relies on a clinically applicable imaging system in combination with a specific tumour-targeting
contrast agent. In this study EpCAM (epithelial cell adhesion molecule) is evaluated as target for FGS in combination with
the novel Artemis imaging system.
Methods: The NIR fluorophore IRDye800CW was conjugated to the well-established EpCAM specific monoclonal
antibody 323/A3 and an isotype IgG1 as control. The anti-EpCAM/800CW conjugate was stable in serum and
showed preserved binding capacity as evaluated on EpCAM positive and negative cell lines, using flow cytometry
and cell-based plate assays. Four clinically relevant orthotopic tumour models, i.e. colorectal cancer, breast cancer,
head and neck cancer, and peritonitis carcinomatosa, were used to evaluate the performance of the anti-EpCAM
agent with the clinically validated Artemis imaging system. The Pearl Impulse small animal imaging system was
used as reference. The specificity of the NIRF signal was confirmed using bioluminescence imaging and
green-fluorescent protein.
Results: All tumour types could clearly be delineated and resected 72 h after injection of the imaging agent.
Using NIRF imaging millimetre sized tumour nodules were detected that were invisible for the naked eye.
Fluorescence microscopy demonstrated the distribution and tumour specificity of the anti-EpCAM agent.
Conclusions: This study shows the potential of an EpCAM specific NIR-fluorescent agent in combination with
a clinically validated intraoperative imaging system to visualize various tumours during surgery.
Keywords: Image-guided surgery, Near-infrared fluorescence, Optical imaging, Epithelial cell adhesion
molecule, Imaging agent
Background
Curative intended oncologic surgery aims to completely
resect all malignant cells. Discriminating tumour from
healthy tissue during surgery is therefore of paramount
importance [1]. As a consequence, clinically complete
resected tumours frequently turn out to be pathological
incompletely removed [2–4]. Therefore, novel intra-
operative imaging modalities are needed that aid the
surgeon in recognizing tumour spread and provide
guidance during tumour removal. Fluorescence-guided
surgery (FGS) is a technique based on near-infrared
(NIR) light, which has been widely investigated for
sentinel lymph node procedures, anastomosis and during
cholecystectomies [5–7]. The advantage of NIR fluorescent
light is the relatively deep tissue penetration and the
minimal tissue auto fluorescence at these wavelengths. The
tissue depth at which a fluorophore can be detected is
dependent on the fluorophore, the tissue optical properties
and the sensitivity of the imaging device. Maximum tissue
penetration detection has been estimated to be between 3
and 4 cm for intensified devices [8] and up to 2 cm for
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others [9]. Further, since NIR fluorescence light is invisible
for the human eye, there is no alteration of the surgical
field [10]. The major challenges for the routine intro-
duction of FGS in the clinic comprise the availability of
validated NIR fluorescence imaging systems in combin-
ation with a dedicated tumour-specific NIR fluorescence
agent [11].
The first NIR imaging systems for clinical application
proved the feasibility of the concept but were in fact
more proto-types than standard clinical equipment. The
next generation NIR imaging systems, as used in this
study, are more versatile, smaller, cheaper, and more
sensitive and should meet uniform standards warranting
an exponential increase for clinical applications. Therefore,
presently the biggest challenge for clinical introduction of
FGS is the development of specific tumour targeting NIR
fluorescent agents that comply with these second gen-
eration imagers. Various established membrane-bound
tumour markers are under evaluation as targets for
(NIR) fluorescence imaging in pre-clinical settings, such
as EGFR, HER2/Neu, VEGF(R), folate receptor alpha,
uPAR and various integrins [12–17]. Although these
proteins have been successfully targeted in human tumours
xenografted in animal models, none of them seems to be
the universal target suited for the majority of tumour
(types) in a clinical setting: These proteins are either
present on the majority of tumours but only on a low
percentage of tumour (stromal) cells, like VEGFR and
αvβ3 integrin, or they are abundantly present in only a
limited percentage of tumour (types), like folate receptor,
EGFR and HER2.
In this study we evaluate Epithelial Cell Adhesion
Molecule (EpCAM) as target for FGS. EpCAM is a
transmembrane glycoprotein involved in cell-cell interac-
tions and cell-stroma adhesion [18]. EpCAM expression is
restricted to epithelial cells and is highly up-regulated in
virtually all epithelial carcinomas [19, 20]. EpCAM up-
regulation is associated with cancer progression and
EpCAM is found on circulating tumour cells and me-
tastases. EpCAM overexpression in cancer cells was
found to be 100- to 1000-fold higher compared to ex-
pression on normal breast cells resulting in 100,000 to
400,000 copies per cell [21]. Compared to an estab-
lished tumour target like EGFR and Her2/Neu this
number is only marginally less. But overexpression of
EGFR and HER2/Neu in primary breast cancer is re-
ported to be 0.8-14 and 15-20% respectively, whereas
40-98% of the primary breast tumours show enhanced
EpCAM levels [20, 22]. For other epithelial cancers
these figures are similar or favour the use of EpCAM as
imaging target even more [20, 23–25]. These findings
have led to the development of many EpCAM specific
antibodies, from which some have been evaluated in
phase I, II and III immunotherapeutic trials in various
cancer types, such as ovarian, gastric and head-and-
neck cancer [26, 27]. The results of these studies did
not meet the high expectations for the therapeutic purpose
and most of these investigations were aborted. Mild ad-
verse effects like nausea, vomiting and elevation of pancre-
atic enzymes have been reported for therapeutic use, but
are not expected in single dose imaging studies. The poten-
tial of EpCAM targeting has recently been re-discovered,
as tumour specific imaging was demonstrated for SPECT
imaging. A monoclonal antibody with medium high affinity
for EpCAM, has been labelled with various radionuclides
and has been extensively evaluated in several xenografted
tumour models in mice [28, 29].
In the current study we conjugated the same monoclonal
antibody 323/A3 to the clinically relevant NIR fluorescent
dye IRDye800CW and evaluated this conjugate in tumour
models of clinically relevant orthotopic colorectal, breast
and head-and-neck cancer models. To simulate clinical
conditions we evaluated the performance of the probe with
the recently introduced commercially available Artemis
imaging system [30] in comparison with the Pearl Impulse
small animal imaging system, a standard apparatus for use
in pre-clinical settings.
Methods
Cell lines
For colorectal, breast and head-and-neck cancer, we
selected two cell lines with different tumour characteristics.
Luciferase transfected cells were used to follow orthotopic
tumour growth by bioluminescence imaging (BLI). MCF-7
and OSC-19 cells were transfected with Luciferase 2 and
green fluorescent protein as described previously [31]. All
cell lines were grown in a humidified incubator at 37 °C
and 5% CO2. Cells were cultured for not more than 10
passages and regularly checked for Mycoplasma infec-
tion by PCR.
EpCAM expression
EpCAM expression of HT29(−/+)luc2, COLO320, OSC-
19-luc2-cGFP, FaDu-luc2, MCF-7-luc2-cGFP and MDA-
MB-231 cells was evaluated by flow cytometry. Cells
were cultured until 90% confluence and detached with
trypsin. Viability of the cells was evaluated using trypan
blue. After adjusting the number of cells to 0.5 × 106 per
tube in ice cold phosphate-buffered saline (PBS), they
were incubated with 0.4 μg/ml 323/A3 anti-EpCAM
antibody or isotype control MOPC21 for 30 min on ice.
Then cells were washed three times in ice cold PBS and
incubated with a goat anti-mouse IgG1-AF488 secondary
antibody (Invitrogen, 2.5 μg/ml). The cells were washed
three times in ice cold PBS and resuspended in 400 μL
PBS containing propidium iodide to exclude dead cells
from the analysis. Flow cytometry was performed using the
LSRII (BD Biosciences). The experiments were performed
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in duplicate and EpCAM expression was estimated as
the geometric mean of fluorescence intensity measured
in 10,000 viable cells. For quantitative determination of
EpCAM numbers per cell type the Qifikit (Dako) was used.
Antibodies and conjugation to IRDye 800CW
EpCAM specific monoclonal chimeric antibody 323/
A3 and the IgG1k isotype control monoclonal antibody
MOPC21 (BioXcell, West Lebanon, USA) were used [32].
Antibody 323/A3 has a medium high affinity (Kα = 2 ×
109 M−1) for EpCAM and is directed against the EGF-like
domain I epitope on the extracellular domain of the
EpCAM molecule, whereas MOPC21 has an unknown
specificity after testing on human and rodent tissues
[33–35]. Both antibodies were covalently conjugated to
NIR fluorochrome IRDye 800CW (LI-COR, Lincoln,
NE, USA). λex = 773 nm, λem = 792 nm) using N-
hydroxysuccinimide ester chemistry as indicated by the
manufacturer. Removal of unconjugated fluorophore
was accomplished by using two Zeba Spin Desalting col-
umns (Thermo Fisher Scientific, Perbio Science Nederland
B.B., Etten-Leur, The Netherlands) per protein in two
sequential steps. For comparison experiments, the two
conjugates i.e. the EpCAM specific (323/A3-800CW)
and control (MOPC21-800CW) were complemented by
the chemically inactive carboxylate version of IRDye
800CW, representing the fluorescent label without anti-
body control.
Serum stability
The stability of 323/A3-800CW in human serum was
evaluated using HPLC (Biosep-SEC-s2000, Phenomenex,
USA). Serum and sodium azide dilution were filtrated
through a 0.22 μm filter in a 15 ml tube. A 24-wells plate
(Greiner Bio-one, Germany) was prepared with 0.02%
sodium azide and serum/probe in a ratio of 1:1 and PBS as
control and incubated at 37 °C under 5% CO2. At 4, 24,
48 and 96 h 20 μl of sample, diluted in 40 μL PBS was eval-
uated using HPLC in PBS at a flow rate of 0,5 ml/min for
60 min, detected at 2 channels, 280 and 780 nm.
Cell binding study
A cell binding assay was performed to confirm the EpCAM
specificity of 323/A3-800CW. HT29-luc2 (40,000 cells),
COLO320 (40,000 cells), OSC-19-luc2-cGFP (25,000 cells),
FaDu-luc2 (35,000 cells), MCF-7-luc2-cGFP (40,000 cells)
and MDA-MB-231 cells (40,000 cells) cells were
seeded in a black 96-well plate (Greiner Bio-one,
Germany). At ±90% confluence the cells were washed
twice with PBS. 323/A3-800CW and MOPC21-800CW
were added in a concentration range of 0–8 μg/ml and
incubated for 1 h at 37 °C. After incubation, the cells were
washed twice with culture medium without supplements.
Bound antibody was imaged with an Odyssey scanner
(LI-COR), scanning at the 800 nm channel. To correct
the fluorescence signal for the number of tumour cells
per well a cell nucleus staining was performed: The cells
were fixed/permeabilized with acetone/methanol for
10 min, washed with PBS, and incubated with TO-PRO-3
(Invitrogen) at 1:1000 for 5 min at room temperature.
After washing twice with PBS, the plate was imaged with
the Odyssey scanner at the 700 nm channel to detect
TO-PRO-3 fluorescence. The ratio of the 800 and 700 nm
fluorescence was plotted. The experiments were performed
in triplicate.
Animal models
Nude Balb/c female mice (Charles River laboratories,
l’Arbresle, France), aged 4–6 weeks, were housed in indi-
vidually ventilated cages and provided with food and
sterilized water ad libitum. Their general health state was
monitored by weight measurements throughout the exper-
iments. Tumour growth was monitored longitudinally by
visual inspection of the tumours, caliper measurements
and/or by bioluminescence imaging. Bioluminescence
imaging was performed by intraperitoneal injecting of
150 mg/kg of D-luciferin solution (SynChem, Inc, Elk
Grove Village, IL) in PBS, in a total volume of 50 μL. After
10 min, mice were imaged with the IVIS Spectrum imaging
system (PerkinElmer, Waltham, MA, USA). Imaging pro-
cedures were performed under isoflurane gas anaesthesia
Colon cancer models
To induce colon tumours, mice were subcutaneously
injected at four sites with 5 × 105 HT29 cells in 40 μL
RPMI1640 medium. Tumour growth was followed by
calliper measurements and after 10 days, when the
tumours reached a volume of approximately 75 mm3,
imaging experiments started. Orthotopic HT29-luc2
tumours were induced as described previously [36].
To induce orthotopic breast tumours, 2.5 × 105 MCF-7-
luc2-cGFP cells were inoculated in two contralateral
mammary fat pads. Oestrogen pellets (17β-
oestradiol, 0.36 mg/pellet, 60 day release) were
implanted subcutaneously. Tumour growth was
followed by visual inspection and bioluminescence
measurements as described above.
Breast carcinoma model
Orthotopic tongue tumours were induced in the tip of the
tongue through a submucosal injection of 4 × 104 OSC-19-
luc2-cGFP cells. When tumours were visible and
bioluminescence signal ranged between 5 × 109 and 1 ×
1010 relative light units (RLU) imaging experiments started.
Peritonitis carcinomatosa
Multiple small MCF-luc2-cGFP tumours were induced
in the peritoneum by intraperitoneal injection of 2.5 × 105
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MCF-luc2-cGFP cells. Tumour growth was followed
twice a week by bioluminescence as described above.
Imaging experiments initiated when multiple tumour
nodules were formed of various sizes.
NIR fluorescence imaging systems
Real-time NIR fluorescence imaging and operative resec-
tion of the tumours was performed using the next gener-
ation Artemis imaging system (Quest Medical Imaging,
Middenmeer, the Netherlands). An earlier iteration of
this system was extensively validated [30]. This system
has a freely moveable handheld camera for simultaneous
acquisition of visible light and NIR fluorescence. Since
the system has been improved such that the camera can
be fixed in a stable position with an arm, while both
camera and arm are covered with a sterile drape. The
illumination efficiency and homogeneity has been im-
proved with a ring containing eight hemispheric illumin-
ation lenses centred around a wide field imaging lens for
open surgery. Illumination is provided by four visible
light sources with peaks centred in the blue, cyan, green
and red and a NIR laser with a peak at 785 nm for fluor-
escence excitation. Reflected excitation light is blocked
by a 750–800 nm notch filter. Captured visible and NIR
light is split using a prism containing a dichroic coating
(<785 mm). Visible light additionally passes through a
low-pass filter (<640 nm) and the NIR emission light is
filtered with a high pass filter (>808 nm). Exposure times
and sensor gains are separately adjustable for both imaging
channels. The visible light channel, the NIR fluorescence
channel and an adjustable overlay of both channels are
simultaneously presented during the procedures.
Next to the Artemis imaging system, the Pearl Impulse
small animal imaging system (LI-COR) was used as a
preclinical reference to visualize tumours and calculate
the tumour-to-background ratios (TBRs). Data from the
Artemis and Pearl imaging systems were analysed using
imageJ (W. Rasband, Bethesda, Maryland) and the Pearl
Cam Software, respectively.
NIR fluorescence measurements
Subcutaneous HT29 colon tumours were used to con-
firm in vivo EpCAM specificity of 323/A3-800CW and
to measure fluorescence over time. When the subcuta-
neous HT29 colon tumours were 36 ± 6 mm2, 1 nmol
(≈150 μg) of 323/A3-800CW (n = 3), 1 nmol (≈150 μg)
MOPC-800CW (n = 3) or 1 nmol (≈1.1 μg) of 800CW
carboxylate was injected intravenously. NIR fluorescence
signals were measured at 0, 4, 24, 48, 72 and 96 h after
injection using the PEARL small animal imaging system
and the intraoperative Artemis imaging system after
which TBRs were calculated.
After in vivo confirmation of the EpCAM specificity
and establishment of the optimal time frame for imaging
with the subcutaneous model, the clinically more relevant
orthotopic MCF-7-luc2-cGFP breast, OSC-19-luc2-cGFP
tongue and HT29-luc2 colon tumours were evaluated.
Hence, 1 nmol of 323/A3-800CW (n = 3) or 1 nmol
MOPC21-800CW (n = 3) was intravenously injected in
each group. Fluorescence imaging of mice bearing orthoto-
pic tumours was performed 72 h after administration for
optimal TBR as determined in the subcutaneous HT29
colon carcinoma model. TBRs of orthotopic tumours were
measured and tumours were resected under NIR fluor-
escence guidance using the Artemis imaging system. Ex
vivo, fluorescent measurements of resected tissue were
performed on a back table. Tumours were sliced and
fluorescence measurements were performed on the sec-
tions to evaluate the distribution of the probe. Resected
tumours from the head-and-neck cancer and breast
cancer models were assessed by BLI imaging and GFP
fluorescence imaging (OSC-19-luc2-cGFP and MCF-7-
luc2-cGFP, IVIS spectrum).
The MCF-luc2-cGFP peritonitis carcinomatosa tumour
model was used to determine the minimal tumour sizes
that could be detected by intra-operative fluorescence
imaging using the EpCAM specific antibody 323/A3-
800CW in combination with 2 imaging systems. Because
an enhanced permeability and retention (EPR) effect in
these micrometases is not expected as indicated recently
by Hall et al. [34] no MOPC21-800CW control was used
in this model. Mice were anesthetized 72 h after intraven-
ous injection of 323/A3-800CW (1 nmol, n = 3), as de-
scribed above and fluorescence imaging using the Pearl
and Artemis imaging system was performed. A midline
abdominal incision was made and the abdominal skin was
removed. Fluorescence imaging of the mice with both im-
aging systems was performed followed by resection of the
peritoneum and again fluorescence images were taken.
Fluorescence imaging of the abdominal area was per-
formed to search for residual intraperitoneal tumour
nodules. Presence of tumour nodules and tumour specific
NIR fluorescence was confirmed by bioluminescence im-
aging and GFP fluorescence imaging, as described before.
Receiver Operator Curve (ROC) analysis was performed
for the detection of micrometastases in the peritoneum.
The overlay of the BLI and GFP signals was used as the
ground truth for tumour metastases and the ascending
TBRs as positive cut off criteria. The area under the curve
(AUC), including the sensitivity and specificity rates at the
optimal TBR cut off were computed. The signals of NIR
fluorescence and the overlay with BLI and GFP was con-
firmed against pathology in the primary tumor but not in
the micrometastases.
Multiple regions of interest were drawn in the tumour
and in adjacent normal tissue and divided by each other
to calculate TBRs. TBRs of subcutaneous colon and ortho-
topic breast tumours were calculated with skin overlying
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the tumour and adjacent normal tissue. Tongue tumours
were imaged through an epithelial cell layer covering the
tumour and normal tissue. For colon tumours the periton-
eum was opened.
In vivo competition study
Three of the six nude Balb/C mice with bilateral orthotopic
MCF-7-luc2-cGFP breast tumours were pre-injected with
unconjugated 323/A3 antibody (1 mg, intraperitoneal,
100 μL). After 48 h, all six mice were intravenously injected
with 1 nmol 323/A3-800CW. Then, 72 h after injection of
323/A3-800CW fluorescence imaging of all mice was per-
formed using a Pearl imaging system. Mice were sacrificed
and tumours were collected. Quantification of fluorescence
was done as described before [37]. In brief, tumours were
resected and lysed with a TissueLyser II system (Qiagen,
Venlo, The Netherlands) using pre-cooled Eppendorf tube
holders, 5-mm stainless steel beads, and RIPA buffer sup-
plemented with a complete EDTA-free mini tablet pro-
tease inhibitor cocktail. Homogenates were serially
diluted in 96-well plates, in parallel with a probe dilu-
tion. The fluorescence intensity of both series was de-
tected at 800 nm using the Odyssey scanner. The
concentration of probe in the homogenates was extrap-
olated from the calibration curves and the concentra-
tion values were used to calculate the injected dose per
gram of tissue (% ID/g) with standard error of the mean
(SEM) indicated per group, based on the volume of the
homogenate and the weight of the tumours.
Histology and NIR fluorescence microscopy
After ex vivo fluorescence measurements, tumours were
snap frozen in isopentane and kept at −80 °C. Tissues
were sectioned at 10 μm and fluorescence imaging was
performed using the Odyssey imager. The presence of
OSC-19-luc2-cGFP and MCF-7-luc2-cGFP tumour cells
was confirmed by fluorescence microscopy (Nikon Eclipse
e800). All histologic sections were stained with standard
haematoxylin-eosin stain (HE) after acetone fixation. To
confirm the presence of HT29 and HT29-luc2 cells, sec-
tions were stained with an anti-human wide-spectrum
cytokeratin antibody (Abcam inc., Cambridge, MA, USA).
Primary antibodies or controls were incubated for 60 min
at room temperature. All slides were three times washed
with PBS and incubated with Envision anti-rabbit (DAKO)
for 30 min at room temperature. Subsequently, the slides
were washed with PBS and staining was visualized by using
3,3-diaminobenzidine. Sections were counterstained with
haematoxylin, dehydrated and mounted with pertex.
Frozen OSC-19-luc2-cGFP and MCF-7-luc2-cGFP tumours
were stained with an anti-cGFP staining (Evrogen, Moscow,
Russia). Sections stained with anti-cGFP were fixated with
4% formalin for 10 min. After washing with PBS, cells were
treated with 0,1% saponin/PBS for 10 min and incubated
with the anti-GFP antibody, diluted in 0,1% saponin/PBS
for 60 min at room temperature. Adjacent sections were
fixated with aceton for 10 min followed by three washes
with PBS and stained for cytokeratin as described before.
Statistical analysis
For statistical analysis, SPSS statistical software package
(version 20.0 for Windows, IBM SPSS Inc, Chicago, USA)
was used. TBRs were calculated by dividing the fluorescent
signal of the tumour by fluorescent signal of surrounding
healthy tissue. TBRs are reported in mean and standard
deviation. A two-way repeated measurement ANOVA was
used to assess the relation between TBRs in the dose
groups and time points. Furthermore a paired Student’s
t-test was used to calculate the overall difference between
the EpCAM specific and control groups. The two-way re-
peated measurement ANOVA was corrected using the
Bonferroni correction. A P-value equal or lower than 0.05
was considered significant.
Results
EpCAM expression on human cancer cell lines
The colon adenocarcinoma cell line HT29 showed inter-
mediate high expression of EpCAM while COLO320
hardly had any EpCAM expression (200,000 versus <1000
EpCAM/cell), see Fig. 1a). For MCF-7 breast cancer cells
similar EpCAM over-expression was observed as for
HT29, whereas considerably less expression was seen in
MDA-MB-231 cells, as described previously (Fig. 1b).
For head-and-neck cancer cells, the human hypopharyngeal
squamous cell carcinoma cell line FaDu-luc2 and the oral
squamous cell carcinoma cell line OSC-19 showed similar
intermediate EpCAM expression (Fig. 1c). For all cancer
cell lines the control antibody MOPC21 showed no signifi-
cant signal. EpCAM expressing cell-lines MCF-7 and OSC-
19 were transfected with GFP and luciferase and were, next
to HT29-luc2 used for further in vivo experiments.
Conjugation, characterization and serum stability of 323/
A3-800CW
Both the EpCAM specific (323/A3) and the control anti-
body (MOPC21) were labelled with IRDye 800CW (Fig. 2a)
in comparable mean dye:antibody ratios of respectively
2.6 ± 0.9 and 2.8 ± 0.9, as determined spectrophotomet-
rically, according to the protocol of the manufacturer
of the dye. Plate assays containing both high and low
EpCAM expressing cell lines were utilized to confirm
EpCAM specificity of 323/A3-800CW after conjugation. A
significant (p < 0.01) difference was observed between
323/A3-800CW and MOPC21-800CW signals on MCF-7,
HT29, OSC-19 and FaDu cells, but not on the low EpCAM
expressing COLO320 and MB-MDA-231 cells (Fig. 2b).
The fluorescence intensity of MOPC21-800CW showed a
slight concentration dependent increase as a result of non-
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specific binding. The results are in accordance to the
EpCAM expression found using flow cytometry results of
the antibodies without 800CW label, as shown in Fig. 1.
The increase in concentration resulted in a plateau in
fluorescence intensity in MDA-MB-231, OSC-19 and FaDu
cells. A further increase in concentration did not increase
signal intensity. This phenomenon was not seen in MCF-7
and HT29 cells, possibly due to the high EpCAM expres-
sion. The EpCAM specific conjugate showed to be stable
in human serum with more than 60% of the conjugate still
free to bind EpCAM after 96 h with the remaining 40%
aggregated or bound to albumin (Fig. 2c).
Intra-operative NIR fluorescence tumour delineation and
resection
In vivo specificity of 323/A3-800CW was shown by compe-
tition with unconjugated antibody. Pre-injection of 1 mg
unconjugated 323/A3, resulted in a decrease of the percent-
age of injected dose per gram of tumour from 3.2 ± 0.9%
ID/g to 1.0 ± 0.1% ID/g (p < 0.01, n = 3 in both groups), see
Fig. 3a. The HT29 subcutaneous tumour model was used
to assess the feasibility of intraoperative fluorescence
delineation using 1 nmol (150ug) intravenous 323/A3-
800CW combined with the Artemis imaging system.
Tumours could be clearly delineated from 4 h post in-
jection and an increase in TBR was seen with highest
values at 72 h post-injection (5.2 ± 0.7, Fig. 3b). After
72 h the TBR slightly decreased. Significant differences
in TBR (p < 0.01) between EpCAM specific (323/A3-
800CW) and non-specific control (MOPC21-800CW)
could be observed from 24 h post injection (TBR 3.2 ±
0.1 and 1.7 ± 0.2 respectively). MOPC21-800CW and
IRDye 800CW showed a significantly lower TBR at all
time points (p < 0.01).
Based on the results from the subcutaneous tumour
model an optimal incubation time of 72 h was used to
evaluate NIR fluorescence in clinically more realistic
orthotopic mouse models for colon, breast and head-and-
neck cancer. After exploration of the tumour, we assessed
the feasibility of fluorescence-guided resection and chose
suitable resection margins with the real-time NIR fluores-
cence feedback of 323/A3-800CW and the Artemis imaging
system. All tumours were radically resected as confirmed
by BLI evaluation. Significant differences (p < 0.01) in TBRs
were observed between the orthotopic colon (HT29)
mice injected with 323/A3-800CW (TBR 13.5 ± 3.6)
and MOPC21-800CW (TBR 1.8 ± 0.4) (Fig. 3c). For the
breast (MCF-7) and head-and-neck (OSC-19) cancer
Fig. 1 EpCAM expression: EpCAM overexpression was present in all cell lines except in COLO320 cells. Expression of EpCAM was analyzed in
human colon (a HT29-luc2, COLO320), breast (b MCF-7, MDA-MB231) and head & neck (c OSC-19, FaDu-luc2) cancer. Cells were incubated with
an anti-EpCAM antibody (323/A3) or an isotype normal mouse IgG (MOPC21). After washing, cells were incubated with fluorescein isothiocyanate
(FITC)-conjugated anti-mouse IgG antibody. The anti-mouse antibody was solely used as a control (conjugate)
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Fig. 3 EpCAM specificity and intra-operative tumor-to-background ratios (TBR’s): Competition with 1 mg of cold 323/A3 antibody significantly
decreased the percentage of injected dose 323/A3-800CW per gram tumor (%ID/g) indicating in vivo tumor specificity a. After development
of subcutaneous HT29-luc2 tumors, 1 nmol (150ug) of 323/A3-800CW, MOPC21-800CW and IRDye 800CW was injected intravenously. TBR’s
were calculated from 4 h to 120 h after injection b. Subsequently, 1 nmol (150ug) 323/A3-800CW and MOPC21-800CW was intravenously
injected in mice bearing orthotopic colon (HT29-luc2), breast (MCF-7-luc2-cGFP) and tongue (OSC-19-luc2-cGFP) tumors c. TBR’s were calculated 72 h
post injection. TBR’s of EpCAM specific antibody 323/A3-800CW in colon, breast and head & neck cancer are significantly higher compared to those of
the control antibody MOPC21-800CW
Fig. 2 Conjugation, serum stability and EpCAM specificity: Conjugation of IRDye 800CW to 323/A3 and MOPC21 was done through NHS ester
conjugation. A mean labeling ratio of 2.6 ± 0.98 and 2.8 ± 0.99 was obtained for 323/A3 and MOPC21 respectively a. EpCAM specificity of 323/A3
was confirmed after conjugation of IRDye 800CW on various cell types, corrected for cell number using the 800/700 nm ratio b. Experiments
were done in human colon (HT29-luc2, COLO320), breast (MCF-7-luc2-cGFP, MDA-MB231) and head & neck (OSC-19-luc2-cGFP, FaDu-luc2) cancer.
Cells were incubated with different concentrations of 323/A3-800CW or an isotype normal mouse IgG (MOPC21) conjugated to 800CW. To correct
for the number of cells, the ratio of NIR fluorescence and the fluorescence intensity of TO-PRO-3 was plotted. 323/A3-800CW showed to be stable in
human serum with more than 60% of the conjugate still free to bind EpCAM after 96 h with the remaining 40% aggregated or bound to albumin c
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models, 323/A3-800CW showed TBRs of 6.7 ± 1.9 and
4.9 ± 0.7 respectively (Fig. 3c). Significantly lower TBR
values of 1.9 ± 0.1 and 1.6 ± 0.2 were observed for
MOPC21-800CW in breast and head-and-neck cancer
respectively (p < 0.01). Examples of in vivo and ex vivo
images that were acquired with the Artemis imaging
system after injection of 323/A3-800CW or MOPC21-
800CW are shown for the orthotopic colon (Fig. 4a and b),
breast (Fig. 4c) and head-and-neck cancer model (Fig. 4d).
Camera exposure time and gain were intra-operatively
adjusted to obtain optimal image contrast. The most im-
portant factors influencing measured fluorescent intensities
were sample fluorescence intensity, camera settings and
the coupled distance to sample of both illumination source
and camera. The Artemis camera is not calibrated for ab-
solute intensity measurements (e.g. in lumen), hampering
absolute intensity comparisons between images.
Detection of small tumour sizes
Four weeks after the intra-peritoneal injection of MCF-7-
luc2-cGFP cells multiple tumours were observed by BLI
imaging. Millimetre size tumour nodules located on the
peritoneum, which were not visual by the naked eye, could
be observed by NIR fluorescence imaging after injection of
1 nmol (150ug) 323/A3-800CW, using both the Pearl and
Artemis imaging system (Fig. 5). After the peritoneum was
resected, BLI confirmed that intra-peritoneal metastases
could be detected by NIR fluorescence imaging (Fig. 5a).
As in Fig. 4, camera exposure time and gain were adjusted
to obtain optimal contrast. ROC curve analysis showed an
accuracy of 98% (area under the curve, p < 0.0001) for
detecting micro metastases with a sensitivity of 93%
and specificity of 92% at the curve’s optimal TBR cut
off value (Fig. 5). A cut off value obtaining the highest
sensitivity of 100% correlates with a specificity of 73%.
Fig. 4 Intra-operative NIR fluorescence delineation of colon, breast and Head & Neck cancer: Colon a, b breast c and head & neck tumors d
could clearly be visualized during operation using EpCAM specific 323/A3-800CW (TBR colon 13.5, breast 6.7 and Head-and-neck 4.9) and the
Artemis imaging system. 323/A3-800CW (A, C, D, 1 nmol) and the non-specific antibody MOPC21-800CW (B, 1 nmol) were intravenously injected. After
an incubation of 72 h NIR fluorescence imaging was performed. Depicted images are: bright light, fluorescence, overlay (fluorescence and bright light), ex
vivo fluorescence and ex vivo overlay. Scale bars are 5 mm. Artemis fluorescence intensities were intra-operatively optimized for optimal con-
trast. Intensities can only be compared within images
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A specificity of 100% on the other hand correlates with
a sensitivity of 84%.
Histology and Immunohistochemistry
Orthotopic tumour tissue was harvested 72 h after injection
of 323/A3-800CW, MOPC21-800CW and IRDye 800CW.
In sections of cGFP transfected breast and tongue tumours,
the presence of tumour tissue was confirmed by anti-cGFP
immunohistochemical staining (brown colour, Fig. 6c and
d). Fig. 6a clearly illustrates NIR fluorescence (indicated in
red) intensity and localization of 323/A3-800CW,
MOPC-800CW and IRDye 800CW in tissue sections of
tongue tumours, surrounded by normal tissue of the
tongue. Fluorescence of 323/A3-800CW co-localized
with the outer part of the tumour bulk and with small
peninsulas of tumour cells (Fig. 6a). Fluorescence inten-
sity of MOPC21-800CW and IRDye 800CW was hardly
visible and did not show association with tumour tissue
(Fig. 6b). In both, breast and colon cancer tissue sec-
tions NIR fluorescence appeared in the outer rim of
tumour tissue. (Fig. 6c and d). In colon cancer clear co-
localization of small tumour islands and NIR fluores-
cence (indicated in red) was observed with 323/A3-
800CW (Fig. 6d). Cytokeratin staining (brown) was
performed to confirm the presence of colonic tumour
cells in sections of orthotopic colon tumours (Fig. 6d).
Discussion
In this study we investigated an EpCAM-specific NIR-
fluorescent agent using a state-of-the-art next generation
clinical NIR imaging system. The recent technical develop-
ments stimulate the use of advanced but affordable imaging
systems in the clinic. The Artemis imaging system simul-
taneously acquires NIR-fluorescent and visible light, gener-
ating a merged image in real-time. Systems like this will
boost the demand for specific tumour probes dramatically.
The EpCAM directed antibody in this study has been
extensively evaluated for imaging of various tumour models
using radionuclides Technetium, Zirconium, Iodium and
Rhenium [28, 29, 38]. Typically, in these experiments
15–20 μg of conjugate was used per mouse to obtain
clear tumour signals in subcutaneous breast, colon and
ovarian tumours. Using the same antibody but conju-
gated to a NIR dye and in combination with a state of
the art NIR-fluorescence imager, we showed that 1 nmol
(=150 μg) clearly identified breast, colon and head-and-
neck cancers, as well as micro-metastases in human
orthotopic xenograft mouse models. The probe/system
combination allowed an accurate demarcation of the
tumours, the recognition of tumour margins, examin-
ation of malignant spread, and identification of micro-
metre sized metastasis or remnant disease.
A probe against a ‘universal’ target facilitates clinical
usability, and prevents time consuming and costly develop-
ment of multiple agents. Although EpCAM is considered
to be a potential target for epithelial derived cancers, not
all epithelial cancers over-express EpCAM enough to out-
flank adjacent normal tissue. But on the other hand not all
tumours of mesenchymal origin are EpCAM negative.
Over-expression of EpCAM was recently observed in all
a b
Fig. 5 Visualization of submillimeter sized intra-peritoneal metastases using EpCAM specific 323/A3-800CW in combination with the Artemis
system: a MCF-7-luc2-cGFP cells were injected intraperitoneal in mice. After the development of multiple tumors, 1 nmol (150ug) 323/A3-800CW
was injected intravenously. NIR fluorescence imaging was performed after 72 h of incubation using the Pearl and Artemis system. Confirmation of
tumor tissue was performed by Green Fluorescent Protein (GFP) fluorescence imaging or Bioluminescence Imaging (BLI) using the IVIS spectrum.
Micrometastases (arrow) of the colon could be discovered by NIR fluorescence imaging after resection of the peritoneum. b ROC curve analysis
of TBR of fluorescent spots in the peritoneum. True positive rate was plotted versus false-positive rate using ascending positive cutoff values.
B = bladder. Scale bars are 5 mm. Artemis fluorescence intensities were intra-operatively optimized for optimal contrast. Intensities can only be
compared within images
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osteosarcomas, half of the angiosarcomas and 62.5% of
the leiomyosarcomas, indicating the broad spectrum of
tumours that might be targeted [39].
In breast cancer, 20% of tumours that seem radically
resected during surgery turn out to be irradically removed
in histologic analyses. Consequently, FGS in breast cancer
could enhance the number of radical resections without in-
creasing margins, thus improving patient’s prognoses and
cosmetic outcomes after lumpectomies and oncoplastic
surgery [3, 40]. As pointed out earlier, in copies per cell
EpCAM can probably not compete with Her2/Neu in the
subpopulation of Her2 positive breast cancers, but in per-
centage of positive breast tumours EpCAM is clearly the
more prevalent target. For head-and-neck cancer a rela-
tively low percentage of tumours is irradically resected
(16%). Due to the many vital structures in the surrounding
tissue, resection margins should be small and FGS targeting
would be of great clinical benefit. EpCAM overexpression
is seen in 62.5% of tongue tumours [23, 41]. In colorectal
cancers 80-100% overexpression of EpCAM is found.
Although irradical resections occur, the main problem is
damage to vital structures in the lower abdomen. Ureteral
injury is a rare but serious complication of lower abdominal
surgery, with a reported incidence varying from 0.7 up to
10% [42]. EpCAM-based FGS of colorectal tumours in
combination with FGS of the ureters could enhance
the number of radical resections while preserving vital
structures.
In our study, we performed a single injection of 1 nmol
(150ug) of 323/A3-800CW to visualize tumours. This is
the equivalent of 0.5 mg/kg for humans when converted
using the body-surface-area method [43]. Using this
dose, subcutaneously located colon tumours were clearly
recognized from 4 h after injection with optimal TBRs at
72 h, showing the feasibility of the agent. The 72-h time-
point was utilized to perform surgery at the orthotopic
colon, breast, and head-and-neck cancer models validating
the results from the subcutaneous model in clinically more
relevant models. At this time point the agent-imaging
system combination was able to indicate small tumour
Fig. 6 Histology: 323/A3-800CW is specifically located in head-and-neck a, b, breast c, and colon d tumors. Tumor tissue was sectioned 72 h after
injection of 323/A3-800CW, MOPC21-800CW or IRDye 800CW. Shown are anti-GFP (brown, head-and-neck cancer, breast cancer) or cytokeratin
(brown, colon cancer) immunohistochemistry stainings and overlays of NIR fluorescence (red) and anti-GFP/cytokeratin stainings. In all tissue a
clear overlap is seen between NIR fluorescence from 323/A3-800CW and anti-GFP immunohistochemistry staining (indicating tumor). NIR fluorescence is
mainly located in the border of tumors and even small tumor islands (*) are NIR fluorescent. A low, non specific fluorescence signal was
observed in sections with MOPC21-800CW and IRDye 800CW (B). T = tumor; N = normal tissue; C = center tumor; B = tumor border. A and B
1× zoom; C and D 10× zoom
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nodules on the peritoneum or in the abdominal cavity
that were otherwise only detectable by bioluminescence
of these cells. Although we did not study the lower
boundary of tumour size that could be detected, tumour
nodules of 1 mm3 could clearly be visualized. Based on the
number of cells in spheroids of that size, we estimate the
minimal number of cells to be detectable above 50,000.
Obviously this detection limit is depending on multiple
factors like the imaging system, optical properties of over-
lying tissue and the probe. Although ROC analysis for the
detection of micrometastases showed an excellent sensitiv-
ity and specificity at the optimal TBR cut off, it should be
noted that the ex vivo detection of micrometastases in the
peritoneum is very opportune, because almost no back-
ground fluorescence is observed in the peritoneum and the
detection of metastases is not compromised by any tissue
depth. Due to the lack of performance standards for clinic-
ally applicable imaging systems as well as imaging agents,
at present, the combination of both is of major importance
for a successful outcome [44, 45].
Although the anti-EpCAM/800CW conjugate performed
well in various tumour types, this probe could still be opti-
mized. The use of antibodies with relatively high affinity,
like 323/A3, might culminate in heterogeneous tumour
staining, concentrated around the tumour vascularization
rather than homogeneous throughout the tumour. The use
of an antibody with low or intermediate EpCAM affinity
for EpCAM might promote a more homogenous distri-
bution and avoid adverse effects at the cost of a lower
total tumour uptake [29, 46]. An improvement in im-
aging accuracy without compromising the total tumour
uptake could be expected by reducing Fc/FcγR interactions
through deglycosylation of antibody-based imaging as
recently demonstrated by Gao et al. [47]. Further, most
EpCAM antibodies target actually the same EGF-like
domain of EpCAM. Antibodies identifying other EpCAM
domains, like the C- domains might improve detection
efficiency [48]. The use of any mouse-derived antibody, like
323/A3, will inevitably induce human anti-mouse anti-
bodies. Although this is not disastrous for imaging pur-
poses, where only one single dose is needed, a chimerized
or humanized version with retained efficacy should be
preferred [29]. Last but not least, fragments of anti-
bodies like Fab or Fab2 could have higher penetration
capabilities compared to full-size antibodies, as shown
for several antibodies including anti-EpCAM [35, 38, 49].
Using antibody fragments would lead to shorter incu-
bation times, making clinical translation more applic-
able. Moreover, recent developments have opened the
way for hybrid molecules like immunoenzymosomes,
consisting of liposomes equipped with 323/A3 Fab
fragments for targeting [50]. Alternative probes for
pre- and intraoperative imaging could also be gener-
ated by conjugation of the antibody with 2 different
labels, one for PET/SPECT and one for NIRF imaging
like has been done recently [34, 35, 51, 52].
Conclusions
FGS is a promising technique to ensure intra-operative
fluorescence feedback of tumour margins. Clinical suc-
cess is only achieved by using a dedicated camera sys-
tem and tumour-specific agents. This study aimed to
achieve complete preclinical validation of an EpCAM
targeting fluorescence agent in combination with a
next-generation Artemis imaging system. We showed
the ability to visualize, primary tumours and millimetre
sized tumour nodules and metastases that were other-
wise invisible for the human eye. As a novel EpCAM
specific optical agent can be used in a wide variety of
tumours, together with the knowledge from previous
clinical trials and the results from this study, this paves
the way for a fast and cost effective clinical translation.
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